Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPhase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
Neuro-Oncology, 10/06/09
Quinn JA et al. – This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5–day dosing regimens of temozolomide (TMZ) in combination with O6–benzylguanine (O6–BG). This study provides the foundation for a phase II trial of O6–BG in combination with a 5–day dosing schedule of TMZ in TMZ–resistant MG.
Related Articles
Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults
BMC Cancer, 10/22/09
Relevance Score: 80%
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Neuro-Oncology, 10/06/09
Relevance Score: 80%
Treatment of recurrent high-grade gliomas
Current Opinion in Neurology, 11/12/09
Relevance Score: 68%
MK886-induced apoptosis depends on the 5-LO expression level in human malignant glioma cells
Journal of Neuro-Oncology, 11/04/09
Relevance Score: 68%
Methyl-L-11C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma
The Journal of Nuclear Medicine, 11/18/09
Relevance Score: 67%
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Radiosurgery and whole brain therapy in the treatment of brainstem metastases
Clinical and Translational Oncology, 11/25/09
Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2
Virchows Archiv, 11/25/09
Role of caspase 8 as a determinant in trail sensitivity of neuroblastoma cell lines
Pediatric Hematology and Oncology, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor